Trypanosomatid Diseases

DISEASE BURDEN, CURRENT TREATMENTS, MEDICAL NEEDS AND STRATEGIC APPROACHES Visceral leishmaniasis: current treatments and needs (Poonam Salotra, Ruchi Singh, Karin Seifert)Chemotherapy of Leishmaniasis. A Veterinary perspective (María Jesús Corral-Caridad, José María Alunda)Pharmacological metabolomics in trypanosomes (Darren J. Creek, Isabel M. Vincent, Michael P. Barrett)Drug design and screening by in silico approaches (Mattia Mori, Maurizio Botta)Computational Approaches and Collaborative Drug Discovery for Trypanosomal Diseases (Sean Ekins, Barry A. Bunin)METABOLIC PECULIARITIES IN THE TRYPANOSOMATID FAMILY GUIDING DRUGInteraction of Leishmania parasites with host cells and its functional consequences (Uta Schurigt, Anita Masic, Heidrun Moll)The function of glycosomes in the metabolism of trypanosomatid parasites and the promise of glycosomal proteins as drug targets (Melisa Gualdrón-López, Paul A.M. Michels, Wilfredo Quiñones, Ana J. Cáceres, Luisana Avilán, Juan-Luis Concepción)The glyoxalase enzymes in trypanosomatids (Marta Sousa Silva, António E. N. Ferreira, Ricardo Gomes, Ana M. Tomás, Ana Ponces Freire, Carlos Cordeiro)The trypanothione-based redox metabolism of trypanosomatids (Marcelo A. Comini, Leopold Flohé)Thiol peroxidases of trypanosomatids (Helena Castro, Ana M. Tomás)Peroxynitrite as a cytotoxic effector against Trypanosoma cruzi: oxidative killing and antioxidant resistance mechanisms (Madia Trujillo, María Noel Alvarez, Lucía Piacenza, Martín Hugo, Gonzalo Peluffo, Rafael Radi)Selenoproteome of Kinetoplastids (Alexei V. Lobanov, Vadim N. Gladyshev)The Replication Machinery of Kinetoplast DNA (Rachel Bezalel-Buch, Nurit Yaffe, Joseph Shlomai)Life and death of Trypanosoma brucei: New perspectives for drug development (Torsten Barth, Jasmin Stein, Stefan Mogk, Caroline Schönfeld, Bruno K. Kubata, Michael Duszenko)VALIDATION AND SELECTION OF DRUG TARGETS IN KINETOPLASTSRational selection of antimicrobial drug targets: unique or conserved? (Boris

Volume Editors:Timo Jäger studied biology at the Technical University of Braunschweig, Germany, where he also received his PhD. He worked as a Postdoc at the German Research Centre for Biotechnology, Braunschweig, and served as Head of Biological Research and Development for MOLISA GmbH in Magdeburg, Germany. His research centered on the redox metabolism of pathogens, function and catalytic mechanism of peroxiredoxins, target evaluation, characterization, and drug development against infectious diseases, especially tuberculosis and trypanosomiasis. He is currently Managing Director of the Coordination Office of the German Centre for Infection Research DZIF in Braunschweig.Oliver Koch studied pharmacy and computer science at the Philipps-University of Marburg, Germany, where he also received his PhD in the field of computer-aided drug design. During his post-doctoral studies, he worked as a scientific software engineer at the Cambridge Crystallographic Data Centre (CCDC) in Cambridge, UK, before joining the drug discovery department at MSD Animal Health Innovation GmbH, Germany. Currently, he is junior research group leader at the faculty of chemistry, TU Dortmund, Germany. His research interests focus on the development and application of computational methods in drug discovery and molecular design.Leopold Flohé studied philosophy, medicine and biochemistry and obtained his MD and the venia legendi for Biochemistry from the University of Tübingen, Germany. He served as Scientific Director for Grünenthal GmbH in Aachen, the German Biotechnology Centre (HZI) in Braunschweig and Molisa GmbH in Magdeburg, Germany, while simultaneously teaching at the local universities. His contributions to science were acknowledged with Honorary Degrees from the Universities of Buenos Aires and Montevideo, the Claudius-Galenus-Preis, the Klaus Schwarz Commemorative Medal, the Science and Humanity Price (OCC) and the Trevor Frank Slater Award and Gold Medal (SFRRI).Paul M. Selzer